Latest News and Updates | Cantargia

* (R) = Regulatory press releases

Sep 29, 2021

(R) Cantargia receives regulatory approval to start TRIFOUR study in triple negative breast cancer

Sep 22, 2021

(R) Cantargia: FDA grants Orphan Drug Designation to nadunolimab for treatment of pancreatic cancer

Sep 16, 2021

(R) Cantargia presents positive interim data for nadunolimab combination therapy at ESMO Congress

Sep 12, 2021

(R) Cantargia: New positive interim results on nadunolimab combination therapy in NSCLC published in abstract for the annual ESMO Congress

Sep 10, 2021

(R) Cantargia receives regulatory approval to start CESTAFOUR clinical study with nadunolimab in combination with chemotherapy

Sep 10, 2021

(R) Cantargia completes patient recruitment to the phase IIa pancreatic cancer extension cohort in the CANFOUR study

Sep 6, 2021

(R) Cantargia expands nadunolimab development in non-squamous NSCLC

Sep 1, 2021

(R) Cantargia strengthens the company management team

Aug 30, 2021

(R) Cantargia reports preclinical data highlighting advantages of nadunolimab mechanism of action

Aug 26, 2021

(R) Cantargia reports first patient treated in CAPAFOUR study investigating combination of nadunolimab with FOLFIRINOX in pancreatic cancer

<< Newer press releases Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye